Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1988 1
1991 1
1999 1
2009 4
2010 1
2014 1
2017 1
2022 2
2023 0
Text availability
Article attribute
Article type
Publication date

Search Results

12 results
Results by year
Filters applied: . Clear all
Page 1
Humoral response to COVID-19 vaccination in MS patients on disease modifying therapy: Immune profiles and clinical outcomes.
Holroyd KB, Healy BC, Conway S, Houtchens M, Bakshi R, Bhattacharyya S, Bose G, Galetta K, Kaplan T, Severson C, Singhal T, Stazzone L, Zurawski J, Polgar-Turcsanyi M, Saxena S, Paul A, Glanz BI, Weiner HL, Chitnis T. Holroyd KB, et al. Among authors: stazzone l. Mult Scler Relat Disord. 2022 Nov;67:104079. doi: 10.1016/j.msard.2022.104079. Epub 2022 Jul 28. Mult Scler Relat Disord. 2022. PMID: 35952457 Free PMC article.
Cyclophosphamide therapy in pediatric multiple sclerosis.
Makhani N, Gorman MP, Branson HM, Stazzone L, Banwell BL, Chitnis T. Makhani N, et al. Among authors: stazzone l. Neurology. 2009 Jun 16;72(24):2076-82. doi: 10.1212/WNL.0b013e3181a8164c. Epub 2009 May 13. Neurology. 2009. PMID: 19439723 Free PMC article.
Daclizumab in treatment of multiple sclerosis patients.
Ali EN, Healy BC, Stazzone LA, Brown BA, Weiner HL, Khoury SJ. Ali EN, et al. Among authors: stazzone la. Mult Scler. 2009 Feb;15(2):272-4. doi: 10.1177/1352458508097468. Epub 2009 Jan 9. Mult Scler. 2009. PMID: 19136546 Clinical Trial.
Smoking and disease progression in multiple sclerosis.
Healy BC, Ali EN, Guttmann CR, Chitnis T, Glanz BI, Buckle G, Houtchens M, Stazzone L, Moodie J, Berger AM, Duan Y, Bakshi R, Khoury S, Weiner H, Ascherio A. Healy BC, et al. Among authors: stazzone l. Arch Neurol. 2009 Jul;66(7):858-64. doi: 10.1001/archneurol.2009.122. Arch Neurol. 2009. PMID: 19597087 Free PMC article.
An expanded composite scale of MRI-defined disease severity in multiple sclerosis: MRDSS2.
Bakshi R, Neema M, Tauhid S, Healy BC, Glanz BI, Kim G, Miller J, Berkowitz JL, Bove R, Houtchens MK, Severson C, Stankiewicz JM, Stazzone L, Chitnis T, Guttmann CR, Weiner HL, Ceccarelli A. Bakshi R, et al. Among authors: stazzone l. Neuroreport. 2014 Oct 1;25(14):1156-61. doi: 10.1097/WNR.0000000000000244. Neuroreport. 2014. PMID: 25100554 Free PMC article.
HLA B*44: protective effects in MS susceptibility and MRI outcome measures.
Healy BC, Liguori M, Tran D, Chitnis T, Glanz B, Wolfish C, Gauthier S, Buckle G, Houtchens M, Stazzone L, Khoury S, Hartzmann R, Fernandez-Vina M, Hafler DA, Weiner HL, Guttmann CR, De Jager PL. Healy BC, et al. Among authors: stazzone l. Neurology. 2010 Aug 17;75(7):634-40. doi: 10.1212/WNL.0b013e3181ed9c9c. Neurology. 2010. PMID: 20713950 Free PMC article.
Sample size requirements for one-year treatment effects using deep gray matter volume from 3T MRI in progressive forms of multiple sclerosis.
Kim G, Chu R, Yousuf F, Tauhid S, Stazzone L, Houtchens MK, Stankiewicz JM, Severson C, Kimbrough D, Quintana FJ, Chitnis T, Weiner HL, Healy BC, Bakshi R. Kim G, et al. Among authors: stazzone l. Int J Neurosci. 2017 Nov;127(11):971-980. doi: 10.1080/00207454.2017.1283313. Epub 2017 Feb 2. Int J Neurosci. 2017. PMID: 28100092
12 results